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Involvement of the Wnt/β-catenin 
and COX-2 pathways in fibrogenesis
Henderson et al., Proc Natl Acad Sci USA 2010; 107: 14309–14314; 
doi:10.1073/pnas.1001520107
Liu et al., J Cell Biol 2010; 190: 693–706; doi:10.1083/jcb.201004082
Fibrosis of the renal parenchyma is among the most frequent mani-
festations of kidney injury. While the origins of the fibroblasts and 
myofibroblasts that replace normal kidney tissue in diseases are 
currently an issue of lively debate, several signaling pathways have 
already been mechanistically implicated in renal fibrogenesis, most 
notably transforming growth factor-β (TGF-β) and angiotensin II. 
Two new articles, one by Henderson et al. and the other by Liu et al., 
provide evidence of additional fibrogenic mechanisms. Recently, 
He et al. reported that renal fibrosis induced by unilateral ureteral 
obstruction upregulated several genes of the Wnt/β-catenin path-
way and that the Wnt antagonist Dickkopf-1 significantly reduced 
β-catenin accumulation and inhibited myofibroblast activation.1 
Similar results have been found in fibrosis in other organs, includ-
ing the lung. Now, Henderson et al. report that, in mice, ICG-001, 
a small molecule that inhibits β-catenin transcription by interfer-
ing with the β-catenin coactivator CREB-binding protein (CBP), 
attenuated bleomycin-induced lung fibrosis while also preserving 
the epithelium. More remarkably, administration of ICG-001 con-
current with bleomycin prevented fibrosis, and late administration 
was able to reverse established fibrosis and significantly improve 
survival. In another article, based on a variety of observations 
suggesting that the physical properties of an organ may influence 
TGF-β signaling as well as fibroblast proliferation and myofibro-
blast activation, Liu et al. tested the hypothesis that stiffening of 
the mechanical environment (long thought to be an outcome of 
fibrosis) may induce cellular responses that promote, amplify, and 
perpetuate fibrosis. In mice, they found that bleomycin-induced 
pulmonary fibrosis increased tissue stiffness sixfold. In vitro, at this 
stiffness range, cultured lung fibroblasts preferentially accumu-
lated at the highest stiffness values (Figure) and transitioned from 
a quiescent state to a state of increased proliferation and matrix 
synthesis. Microarray analysis suggested involvement of PTGS2, 
the gene that encodes the cyclooxygenase-2 (COX-2) enzyme, and 
additional work confirmed that increasing matrix stiffness strongly 
suppressed fibroblast expression of COX-2 as well as synthesis of 
prostaglandin E2 (PGE2), an autocrine inhibitor of fibrogenesis. In 
addition, Liu et al. found that exogenous PGE2 or an agonist of the 
prostanoid EP2 receptor completely counteracted the proliferative 
and matrix synthetic effects of increased stiffness. This study shows 
an important role for normal tissue compliance, acting via PGE2, 
in maintenance of fibroblast quiescence.
Needless to say, both studies point to exciting avenues of 
research for the treatment of organ fibrosis, a condition that 
defies effective management.
Juan Oliver
1J Am Soc Nephrol 2009; 20: 765–776.
Epigenetic basis for the 
upregulation of autoantigen  
genes in ANCA vasculitis
Ciavatta et al., J Clin Invest 2010; 120: 3209–3219; doi:10.1172/JCI40034
Circulating antineutrophil cytoplasmic autoantibodies (ANCAs) 
can cause necrotizing systemic vasculitis, which is frequently asso-
ciated with crescentic glomerulonephritis. Work over the past sev-
eral years has shown that proteinase 3 (PR3) and myeloperoxidase 
(MPO) are the major ANCA autoantigens, and that both proteins 
are present in neutrophil granules. Interestingly, the protein con-
tent of these granules varies depending on the stage of neutrophil 
development, and PR3 and MPO are predominantly expressed 
during the myeloblast and promyelocyte stages. Indeed, in contrast 
to the normally silenced state of these two genes in mature neu-
trophils of healthy subjects, PR3 and MPO are aberrantly expressed 
in mature neutrophils of patients with ANCA vasculitis. Like all 
cells, neutrophils readily respond to external stimuli with variable 
transcriptional responses. This dynamic nature in gene expression 
suggests that proper silencing mechanisms must be in place to 
ensure that genes silenced during myelopoiesis remain silenced. Cia-
vatta et al. used the aberrant expression of PR3 and MPO in patients 
with ANCA vasculitis to test whether epigenetic gene silencing nor-
mally occurs in neutrophils and whether it may be disrupted in 
these patients. They found that levels of the chromatin modification 
trimethylated histone H3 at lysine 27 (H3K27me3), which is asso-
ciated with gene silencing, were depleted at PR3 and MPO loci in 
ANCA patients compared with healthy controls. Conversely, they 
found that the demethylase specific for H3K27me3 (JMJD3) was 
preferentially expressed in ANCA patients versus healthy controls. 
To examine the possibility that the increased PR3 and MPO expres-
sion and decreased H3K27me3 could be a consequence of ANCA 
vasculitis rather than a pathogenic mechanism, they examined an 
animal model of MPO-ANCA in which necrotizing and crescen-
tic glomerulonephritis was induced in normal mice by injection of 
anti-MPO IgG. They found that these animals developed ANCA 
disease without an increase in Mpo message.
Collectively, these and additional data strongly suggest that epi-
genetic modifications associated with gene silencing are perturbed 
Fibroblasts preferentially accumulate across stiffness gradient. Lung 
fibroblasts stained with phalloidin (red; F-actin) and Hoechst 33342 
(blue; nuclei). Cells attach uniformly across the stiffness gradient 4 hours 
after seeding, but after 120 hours, they accumulate preferentially to 
stiffest region. 
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at ANCA autoantigen-encoding genes, potentially contributing to 
inappropriate expression of PR3 and MPO in patients with ANCA.
Juan Oliver
Serial measurement of growth-
differentiation factor-15 in heart 
failure: relation to disease severity 
and prognosis in the Valsartan 
Heart Failure Trial
Anand et al., Circulation 2010; 122: 1387–1395;  doi:10.1161/
CIRCULATIONAHA.109.928846
Under normal conditions, growth-differentiation factor-15 (GDF-
15) is weakly expressed in most tissues; however, its expression 
increases dramatically in response to tissue injury. Ischemia, 
mechanical stress, angiotensin II, and inflammatory cytokines 
increase the expression of GDF-15 in cardiac myocytes. Yet, while 
GDF-15 is produced in myocytes, it also has been detected in mac-
rophages within atherosclerotic plaques and is induced by oxidized 
low-density lipoprotein and proinflammatory cytokines. GDF-15 
is associated with prognosis in patients with cardiovascular dis-
ease. Anand et al. looked at the association between GDF-15 and 
outcomes among patients enrolled in the Valsartan Heart Failure 
Trial (Val-HeFT), which randomized 5010 patients with heart 
failure to evaluate the efficacy of the angiotensin receptor blocker 
valsartan. GDF-15 was measured from stored samples at baseline 
and at 4, 12, and 18 months after randomization. In a multivari-
able model at baseline, higher GDF-15 values were associated with 
lower estimated glomerular filtration rate, body mass index, and 
serum sodium. Greater GDF-15 values were also associated with 
increasing age, increasing C-reactive protein (CRP), the presence 
of diabetes mellitus, and increasing levels of norepinephrine, uric 
acid, and B-type natriuretic peptide (BNP), as well as a more severe 
class of New York Heart Association heart failure. Increasing GDF-
15 was associated with a greater risk of both mortality and first 
cardiovascular event. This relationship was slightly diminished, 
though still significant, when controlled for multiple clinical and 
demographic factors but was markedly diminished when control-
led for BNP, CRP, and other cytokines that could potentially be 
part of the mechanistic cascade. Increases in GDF-15 at 12 months 
were associated with an increase in BNP and uric acid as well as 
higher baseline CRP. An increase in GDF-15 at 12 months was 
associated with a decrease in glomerular filtration rate, hemo-
globin, and systolic blood pressure. In unadjusted and adjusted 
models, a greater change of GDF-15 was associated with mortality 
and first comorbid events. The relationship stayed significant in 
fully adjusted models and models that adjusted for baseline static 
terms that could be a part of the same mechanistic cascade. The 
relationship, however, was markedly weakened when also adjusted 
for changes in these cytokines, such as BNP and CRP.
The relationship between GDF-15 and outcomes as well as the 
relationship between GDF-15 and kidney function may make it 
a useful biomarker. The analysis of GDF-15 and its clinical utility 
is still in a very early state. For it to be useful among patients with 
chronic kidney disease and end-stage renal disease, research needs 
to focus on its utility in these groups as well as how it supplements 
currently available biomarkers.
Lynda Szczech
Steroid pretreatment of organ 
donors to prevent postischemic 
renal allograft failure:  
a randomized, controlled trial
Kainz et al., Ann Intern Med 2010; 153: 222–230
It is not fully understood why kidneys from living donors have 
a longer graft survival than those from deceased donors. One 
major difference between the donor sources is the incidence of 
postischemic acute renal failure (ARF) in allograft recipients, also 
known as delayed graft function. In a recent paper, Kainz and his 
colleagues conducted a multicenter, randomized, blinded, pla-
cebo-controlled study to determine whether pretreating deceased 
donors with corticosteroids before organ retrieval reduces inflam-
mation and the subsequent rate of delayed graft function after 
engraftment. Deceased heart-beating organ donors received an 
intravenous infusion of saline or methylprednisolone at least 3 
hours before organ harvesting. Kidney biopsies from steroid-
treated donors showed suppression of immune response and 
inflammation (assessed on a genome-wide basis), but the inci-
dence of ARF in the first week after transplantation was similar 
(Figure) in recipients of organs from steroid-treated and saline-
treated donors. Limitations of the study include that donors and 
recipients were mainly white, and all were from three transplanta-
tion centers in central Europe, which may limit generalizability.
This very well-designed study concludes that routinely pre-
treating deceased organ donors with corticosteroids cannot be 
recommended.
Marc De Broe
Trajectories of serum creatinine levels in the first week after 
transplantation, by therapy. Values from the days after dialysis were 
multiplied by 1.2. The P value was derived from the mixed linear model for 
longitudinal data (treatment effect). To convert serum creatinine values to 
mg/dl, divide by 88.4. CI, confidence interval.
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